California Public Employees Retirement System Acquires 3,200 Shares of Momenta Pharmaceuticals, Inc. (MNTA)

California Public Employees Retirement System increased its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 136,400 shares of the biotechnology company’s stock after purchasing an additional 3,200 shares during the period. California Public Employees Retirement System owned 0.18% of Momenta Pharmaceuticals worth $1,903,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new position in shares of Momenta Pharmaceuticals during the fourth quarter valued at approximately $344,000. Crossmark Global Holdings Inc. boosted its stake in shares of Momenta Pharmaceuticals by 39.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $335,000 after purchasing an additional 6,813 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Momenta Pharmaceuticals by 26.4% during the fourth quarter. Fisher Asset Management LLC now owns 124,507 shares of the biotechnology company’s stock valued at $1,737,000 after purchasing an additional 25,984 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Momenta Pharmaceuticals by 4.5% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 409,519 shares of the biotechnology company’s stock valued at $5,713,000 after purchasing an additional 17,727 shares in the last quarter. Finally, Sicart Associates LLC bought a new position in shares of Momenta Pharmaceuticals during the fourth quarter valued at approximately $279,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Stifel Nicolaus raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $18.00 to $21.00 in a research report on Thursday, February 22nd. ValuEngine raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $15.33.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 3,938 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $16.46, for a total value of $64,819.48. Following the completion of the transaction, the chief executive officer now owns 239,869 shares of the company’s stock, valued at $3,948,243.74. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott M. Storer sold 3,972 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $15.16, for a total transaction of $60,215.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,502 shares of company stock valued at $1,661,696. Corporate insiders own 4.40% of the company’s stock.

Shares of MNTA stock opened at $16.75 on Friday. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $19.25. The company has a market cap of $1,444.94, a P/E ratio of -13.73 and a beta of 1.72.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The company had revenue of $64.60 million during the quarter, compared to analysts’ expectations of $66.59 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was up 88.9% compared to the same quarter last year. analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3295119/california-public-employees-retirement-system-acquires-3200-shares-of-momenta-pharmaceuticals-inc-mnta.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Safestore  Reaches New 1-Year High at $539.50
Safestore Reaches New 1-Year High at $539.50
Privatix  Price Hits $5.83 on Exchanges
Privatix Price Hits $5.83 on Exchanges
Comparing Continental Building  and USG
Comparing Continental Building and USG
Babcock & Wilcox  vs. Vivint Solar  Financial Contrast
Babcock & Wilcox vs. Vivint Solar Financial Contrast
Critical Analysis: A10 Networks  and Silicom
Critical Analysis: A10 Networks and Silicom
Digital Credits One Day Volume Reaches $9.00
Digital Credits One Day Volume Reaches $9.00


© 2006-2018 Ticker Report. Google+.